An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study

Description

This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable). Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many studies that have evaluated treatments for cancer-related weight and muscle loss have aimed to treat all patients with weight loss exactly the same and, unfortunately, have not been successful. Like different cancer types, weight and muscle loss related to cancer may have different causes in different individuals and the best treatment strategy for this condition may not be a one-size-fits-all approach. Information gathered from this study may help researchers develop new diagnostic criteria for CC and design better treatments and clinical trials for cancer-related weight and muscle loss in the future to improve the quality of life in patients with advanced colorectal, lung, or pancreatic cancer.

Conditions

Cancer Cachexia (CC)

Talk to us

Study Overview

On this page

Study Details

Study overview

This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable). Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many studies that have evaluated treatments for cancer-related weight and muscle loss have aimed to treat all patients with weight loss exactly the same and, unfortunately, have not been successful. Like different cancer types, weight and muscle loss related to cancer may have different causes in different individuals and the best treatment strategy for this condition may not be a one-size-fits-all approach. Information gathered from this study may help researchers develop new diagnostic criteria for CC and design better treatments and clinical trials for cancer-related weight and muscle loss in the future to improve the quality of life in patients with advanced colorectal, lung, or pancreatic cancer.

Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia

An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study

Condition
Cancer Cachexia (CC)
Intervention / Treatment

-

Contacts and Locations

Urbana

Carle Cancer Center NCORP (CARLE), Urbana, Illinois, United States, 61801

Grand Rapids

Cancer Research Consortium of West Michigan (CRCWM), Grand Rapids, Michigan, United States, 49503

Columbus

Columbus NCORP (COLUMBUS), Columbus, Ohio, United States, 43215

Green Bay

Cancer Research of Wisconsin and Northern Michigan Consortium (CROWN), Green Bay, Wisconsin, United States, 54301

Milwaukee

Aurora NCORP (AURORA), Milwaukee, Wisconsin, United States, 53226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * • Have a primary diagnosis of unresectable or stage IV 1) non-small cell lung cancer (NSCLC), 2) pancreatic adenocarcinoma, or 3) colorectal cancer
  • * Note: Patients do not need to have cachexia to be eligible
  • * NOTE: Patients who received systemic anti-cancer therapy previously as part of adjuvant or neoadjuvant treatment and have since recurred are still eligible if such treatment ended \> 6 months prior to enrollment. Patients receiving concurrent radiation with systemic therapy or receive local therapy alone (surgery, radiation therapy \[RT\]) prior to first line therapy remain eligible. Patients receiving maintenance treatment after first line therapy are not eligible
  • * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • * Be able to understand, speak and read English
  • * Be 18 years of age or older
  • * • Have contraindications to physical function assessments (30-second arm curl, Timed-Up-And-Go test, or 30-second chair-stand test) per the treating provider or their designee
  • * Have any planned major surgeries within the next 3 months
  • * Have received chemotherapy or surgery for separate primary cancer within the past 3 years other than early local staged non-melanoma skin cancer
  • * Be pregnant

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Rochester NCORP Research Base,

Richard Dunne, MD, MS, STUDY_CHAIR, University of Rochester NCORP Research Base

Study Record Dates

2028-01-01